GlassScriptPhysician profile
Timothy O Herron
NPI 1386105906
$3,195.40
in general payments reported to CMS, 2019-2025
23 companies · $997 in 2025
The $997 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $150 · 2023: $778 · 2024: $1,270 · 2025: $997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,045.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $668.92 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $315.88 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $292.86 | 2023-2025 | |
| Exact Sciences Corporation | $260.38 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $247.21 | 2022-2025 | |
| Abbott Laboratories | $225.46 | 2024-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $203.60 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $198.95 | 2023-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $162.83 | 2022-2024 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $156.69 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Corcept Therapeutics | $140.29 | 2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $54.02 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Vanda Pharmaceuticals INC. | $37.86 | 2025 | Fanapt |
| Scilex Pharmaceuticals INC. | $36.20 | 2023 | Ztlido |
| Merck Sharp & Dohme LLC | $32.61 | 2024 | Lagevrio, Vaxneuvance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.25 | 2022-2023 | Jardiance |
| Bausch Health US, LLC | $26.72 | 2023 | Wellbutrin, Aplenzin |
| Dynavax Technologies Corporation | $22.61 | 2023-2024 | Heplisav-B |
| Edwards Lifesciences Corporation | $18.71 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Azurity Pharmaceuticals, INC. | $16.13 | 2023 | Edarbi |
| Alk-Abello, INC | $15.87 | 2025 | Neffy, Grastek, Odactra |
| Tris Pharma INC | $15.25 | 2022 | |
| Almatica Pharma LLC | $15.10 | 2024 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy O Herron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.